Get the Stockscreener App
1.99
6.42%
0.12
Zentalis Pharmaceuticals Inc stock is traded at $1.99, with a volume of 1.09M.
It is up +6.42% in the last 24 hours and up +39.16% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.87
Open:
$1.87
24h Volume:
1.09M
Relative Volume:
1.18
Market Cap:
$143.55M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.4383
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
+25.16%
1M Performance:
+39.16%
6M Performance:
-14.22%
1Y Performance:
-35.39%
1-Day Range:
$1.84
$2.05
1-Week Range:
$1.55
$2.05
52-Week Range:
$1.01
$5.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.99 | 118.30M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals Inc. Price Targets Raised After ReboundFed Meeting & Community Consensus Trade Alerts - newsyoung.net
Using data tools to time your Zentalis Pharmaceuticals Inc. exitJuly 2025 Trends & Community Consensus Picks - Newser
Can volume confirm reversal in Zentalis Pharmaceuticals Inc.Trade Analysis Summary & Scalable Portfolio Growth Ideas - Newser
Using flow based indicators on Zentalis Pharmaceuticals Inc.Trade Entry Report & Reliable Price Action Trade Plans - Newser
Will Zentalis Pharmaceuticals Inc. outperform the marketDollar Strength & High Yield Equity Trading Tips - Newser
Is Zentalis Pharmaceuticals Inc. reversing from oversold territory2025 Trading Volume Trends & Daily Growth Stock Tips - Newser
Risk vs reward if holding onto Zentalis Pharmaceuticals Inc.July 2025 News Drivers & Weekly Chart Analysis and Trade Guides - Newser
How to use a screener to detect Zentalis Pharmaceuticals Inc. breakoutsJuly 2025 Fed Impact & Low Drawdown Investment Ideas - Newser
Intraday pattern recognizer results for Zentalis Pharmaceuticals Inc.Market Movement Recap & Detailed Earnings Play Alerts - Newser
Can Zentalis Pharmaceuticals Inc. Bounce Back From Weekly LowJuly 2025 Rallies & Risk Managed Trade Strategies - Newser
Detecting support and resistance levels for Zentalis Pharmaceuticals Inc.Weekly Market Outlook & Momentum Based Trading Ideas - Newser
Zentalis Pharmaceuticals Inc. stock outlook for YEARQuarterly Earnings Summary & Capital Efficient Trading Techniques - Newser
Visualizing Zentalis Pharmaceuticals Inc. stock with heatmapsWeekly Volume Report & Expert Approved Momentum Trade Ideas - Newser
When is the best time to exit Zentalis Pharmaceuticals Inc.Earnings Recap Report & Consistent Return Strategy Ideas - Newser
Applying Wyckoff theory to Zentalis Pharmaceuticals Inc. stockPortfolio Risk Summary & Daily Stock Trend Watchlist - Newser
Sentiment analysis tools applied to Zentalis Pharmaceuticals Inc.Bull Run & Fast Momentum Entry Tips - Newser
Is Zentalis Pharmaceuticals Inc. a good stock for dollar cost averaging2025 Technical Overview & Weekly Momentum Stock Picks - thegnnews.com
Can Zentalis Pharmaceuticals Inc. weather a recessionTrade Exit Report & Expert-Curated Trade Recommendations - mustnews.co.kr
How to integrate Zentalis Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Earnings & Precise Buy Zone Identification - Newser
Has Zentalis Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewMarket Performance Summary & Risk Controlled Swing Alerts - Newser
Custom watchlist performance reports with Zentalis Pharmaceuticals Inc.July 2025 Selloffs & Safe Entry Point Identification - Newser
What makes Zentalis Pharmaceuticals Inc. stock price move sharplyMarket Movers & Risk Managed Trade Strategies - sundaytimes.kr
Analyzing recovery setups for Zentalis Pharmaceuticals Inc. investorsWeekly Stock Analysis & Community Verified Trade Signals - Newser
Can a trend reversal in Zentalis Pharmaceuticals Inc. lead to recovery2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Published on: 2025-08-15 04:37:23 - Newser
What are the risks of holding Zentalis Pharmaceuticals Inc.Profit Target & Consistent Income Trade Recommendations - kangso.co.kr
Using economic indicators to assess Zentalis Pharmaceuticals Inc. potentialWeekly Trade Report & Weekly Sector Rotation Insights - Newser
Price Clustering Detected in Zentalis Pharmaceuticals Inc. StockMarket Risk Analysis & Fast Entry Momentum Alerts - 선데이타임즈
Is Zentalis Pharmaceuticals Inc. stock a smart retirement pickROI Focused Stock Opportunities - mustnews.co.kr
Wells Fargo & Company Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - MarketBeat
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):